Abstract
AbstractsPatients with mutations in theTMPRSS3gene suffer from recessive deafness DFNB8/DFNB10 for whom cochlear implantation is the only treatment option. Poor cochlear implantation outcomes are seen in some patients. To develop biological treatment for TMPRSS3 patients, we generated a knock-in mouse model with a frequent human DFNB8TMPRSS3mutation. TheTmprss3A306T/A306Thomozygous mice display delayed onset progressive hearing loss similar to human DFNB8 patients. Using AAV2 as a vector to carry a humanTMPRSS3gene, AAV2-hTMPRSS3injection in the adult knock-in mouse inner ears results inTMPRSS3expression in the hair cells and the spiral ganglion neurons. A single AAV2-hTMPRSS3injection in agedTmprss3A306T/A306Tmice leads to sustained rescue of the auditory function, to a level similar to the wildtype mice. AAV2-hTMPRSS3delivery rescues the hair cells and the spiral ganglions. This is the first study to demonstrate successful gene therapy in an aged mouse model of human genetic deafness. This study lays the foundation to develop AAV2-hTMPRSS3gene therapy to treat DFNB8 patients, as a standalone therapy or in combination with cochlear implantation.
Publisher
Cold Spring Harbor Laboratory
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献